Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Study

Basit Öğe Kaydı
dc.contributor.authorDevrimci-Ozguven, Halise
dc.contributor.authorAtmaca, Murad
dc.contributor.authorBaran, Zeynep
dc.contributor.authorCengisiz, Cengiz
dc.contributor.authorCinar, Cem
dc.contributor.authorErol, Atila
dc.contributor.authorGenc, Yasin
dc.date.accessioned2024-04-24T17:08:17Z
dc.date.available2024-04-24T17:08:17Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose The aim of the study was to assess efficacy and safety of paliperidone palmitate (PP) in schizophrenic patients using real-life data. Methods This national, multicenter, retrospective, and mirror-image study was performed reviewing the medical records of patients in 18 centers. Adult schizophrenic patients receiving PP treatment (n = 205) were enrolled. Patients' data covering the last 12 months before the initial PP injection and the period until the end of study with at least 12 months after the initial PP injection were evaluated. Patients' characteristics, scale scores, and adverse events were recorded. Results Nonadherence to prior medication was the most frequent reason for switching to PP treatment. Comparing with the period before PP treatment, the rate of patients visiting the hospital for relapse (79.5% vs 28.9%, P < 0.001) and the median number of hospitalizations (2 vs 0, P < 0.001) were lower during PP treatment. During PP treatment, the Positive and Negative Syndrome Scale score decreased by 20% or more (response to treatment) in 75.7% of the patients. The frequency of adverse events did not differ between the period before and during PP treatment. Improvement in functionality was higher in those with disease duration of 5 years or less. Conclusions Paliperidone palmitate is effective and safe in treatment of schizophrenic patients and in switching to PP treatment in patients with schizophrenia, which reduced the percentage of patients admitted to the hospital for relapse and the median number hospitalization, and has positive effects on functionality.en_US
dc.description.sponsorshipJanssen Cilagen_US
dc.description.sponsorshipThe study was supported by Janssen Cilag.en_US
dc.identifier.doi10.1097/JCP.0000000000001133
dc.identifier.endpage610en_US
dc.identifier.issn0271-0749
dc.identifier.issn1533-712X
dc.identifier.issue6en_US
dc.identifier.pmid31688391
dc.identifier.scopus2-s2.0-85074963921
dc.identifier.scopusqualityQ2
dc.identifier.startpage604en_US
dc.identifier.urihttps://doi.org/10.1097/JCP.0000000000001133
dc.identifier.urihttps://hdl.handle.net/11468/17287
dc.identifier.volume39en_US
dc.identifier.wosWOS:000497512300012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Clinical Psychopharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSchizophreniaen_US
dc.subjectLong-Acting Injectable Antipsychoticen_US
dc.subjectPaliperidone Palmitateen_US
dc.titleEfficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Studyen_US
dc.titleEfficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu